Connect with us

MARKETS

Tilray Inc (NASDAQ:TLRY) Weakens Further Despite Alef Move

Published

on

In our last piece on Tilray Inc (NASDAQ:TLRY), we said we thought this was a bad stock that would be headed lower. It has declined about $30/share since then. The latest drop comes despite the company’s announcement that it has completed an acquisition of its existing import and distribution partner Alef Biotechnology SpA.

According to the releaes, “The acquisition will allow Tilray to import, produce and distribute Tilray branded medical cannabis products in Chile and to create a hub to distribute Tilray products throughout Latin America. Tilray purchased all the outstanding equity of Alef for approximately C$5,000,000 (Canadian dollars). The purchase was comprised of approximately C$250,000 in cash paid at closing, and C$4,750,000 in Tilray Class 2 common stock, subject to a standard working capital adjustment and Alef achieving certain business milestones within a twelve-month period after closing.”

Tilray Inc (NASDAQ:TLRY) engages in the research, cultivation, processing, and distribution of medical cannabis.

The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.

According to the company’s IPO announcement, “Tilray, Inc., a vertically-integrated and federally-licensed cannabis cultivator, processor and distributor, today announced the pricing of its initial public offering of 9,000,000 shares of Class 2 common stock. 6,524,000 shares of Class 2 common stock will be offered in the United States and certain other countries except Canada at a price to the public of US$17.00 per share for a total offering size of US$110,908,000 and 2,476,000 shares of Class 2 common stock, which we refer to as Subordinate Voting Shares, will be offered in Canada and certain other countries except the United States at a price to the public of CAD$22.451 per share for a total offering size of CAD$55,586,200. Based on current exchange rate1, the total combined offering size is approximately US$153,000,000.00.”

One of its key subsidiaries is High Park, which was launched to produce and distribute world-class cannabis brands and products for the Canadian market. Based in Toronto and led by a team with deep experience in cannabis and global consumer brands, High Park has secured the exclusive rights to produce and distribute a broad-based portfolio of cannabis brands and products in Canada, subject to applicable laws and regulations.

In addition, High Park has developed new brands and products for the Canadian market. Upon the coming into force of federal legalization of cannabis for adult-use and corresponding provincial legislation, High Park anticipates fulfilling adult-use supply agreements and purchase orders in Quebec, Ontario, British Columbia, Manitoba, Nova Scotia, Prince Edward Island, Northwest Territories and Yukon on October 17, 2018.

 

The Storm Before the Calm

In our section above, we noted that TLRY just announced that it has completed an acquisition of its existing import and distribution partner Alef Biotechnology SpA. While this is far from market-moving news, we would note that the stock got hit badly on it, dropping nearly 8%.

We would suggest that this is another sign of the stock’s inability to sustain its current pricing, especially with the prospect of Aurora Cannabis now possibly moving toward an NYSE IPO before long.

Nonetheless, from a birds-eye view, shares of the stock are still up about 35% over the past month, despite being up and down more than that in a week for most weeks of that roller coaster month.

“Today’s announcement marks another milestone for Tilray as we expand our global footprint and solidify our presence in Latin America by officially welcoming Alef to the Tilray team,” said Brendan Kennedy, President and Chief Executive Officer of Tilray. “The Chilean government has been a pioneer legitimizing and regulating medical cannabis in Latin America, and we are thrilled to be investing in one of the region’s most exciting markets for biopharmaceutical development.”

Tilray Inc (NASDAQ:TLRY) pulled in sales of $9.7M in its last reported quarterly financials, representing top line growth of 24.8%. However, the company is battling some balance sheet hurdles, with cash levels of 25.3M struggling to keep up with current liabilities at $62.8M.

Business

Phoenix Life Sciences International (OTC: PLSI)

Published

on

In the healthcare sector, Phoenix Life Sciences International Limited operates as a Biotech and Pharma company. It engages in research on organically produced plants such as cannabis and manufactures and distributes adaptive healthcare solutions. Its natural healthcare solutions are targeted at a wide array of conditions including diabetes, pain, cancers, and gastrointestinal problems. For the next five years, the company aims to expand its services to at least 2.5 million patients around the world.

The shares of the company are available for trading over the counter (OTC) under the ticker symbol “PLSI.” It has its headquarters in Denver, Colorado.

Industry Overview
The healthcare sector has been traditionally stable. Companies in the biotech and pharmaceutical industry especially have experienced tremendous advances in recent years. The fast-growing cannabis industry has contributed in many ways to the growth of pharmaceutical and biotech firms. Many of them are investing millions in the medical cannabis market to develop cannabinoid products.

The prospect in the cannabis market is great and should be explored. And Phoenix Life Sciences International Limited is doing that.
P
LSI: A Successful Product of Strategic Partnerships
The most recent of Phoenix Life Sciences International Limited’s (PLSI) deals came through on June 4, 2019. The company announced it had signed an exclusive 25-year Diabetes Management Program deal with the Ministry of Health of the Republic of Vanuatu.

As part of the deal, it would also be granted a global medical cannabis export license. Vanuatu is estimated to have over 50,000 Type 2 diabetics and an expected 50,000 high-risk pre-diabetics. This deal is in furtherance of the company’s strategy of international market expansion.

Financials Indicate Long-Term Growth
For the nine months ended November 30, 2018, Phoenix Life Sciences International Limited did not report its revenues. However, it recorded a net loss of $3.3 million mainly due to an increase in operations expenses. Basic Earnings per Share (EPS) also decreased during the same period.

Following the 2018 merger and consolidation, to realise its plans to uplist to the OTCQB market, the company recently filed its 2017 and 2018 quarterly reports, and will also be subsequently making filings to stay current with its reporting requirements with the SEC. Uplisting will enable the company to access more funds for the execution of its next developmental stages.
Conclusion

The fundamentals of Phoenix Life Sciences International Limited are not presently attractive. The company is being burdened with rising operations expenses. This is expected as the company just passed through a major restructuring process and is focused on expanding to international markets.
The international expansion efforts should result in increased revenues. The uplisting would also create more access to funds. Both would contribute to long-term growth.

Moreover, at the current market price of $10.24, the company (OTC: PLSI) is trading far away from its 52-week high of $48.25, meaning a lot of upside potential. Hence, for the long-term investor, this might be a good time to buy.

Continue Reading

MARKETS

The Bounce Takes Hold in Medmen Enterprises Inc (OTCMKTS:MMNFF) on Geographic Expansion

Published

on

Medmen Enterprises Inc (OTCMKTS:MMNFF) has been one of our favorite ideas in the cannabis space in this pullback because the company’s strong geographic diversification in the US marketplace. As a case in point, the company just announced that it has signed a definitive agreement to acquire control of Kannaboost Technology Inc., giving the company a stronghold in the Arizona market.

According to the company’s most recent press release, “Level Up holds licenses for two vertically-integrated operations in Arizona, which include retail locations in Scottsdale and Tempe, as well as 25,000 square feet of cultivation and production capacity in Tempe and Phoenix. As part of the transaction, the Company will also receive a 40 percent stake in top-selling brand K.I.N.D. Concentrates (“K.I.N.D.”), which is currently distributed in over 90 percent of the dispensaries in Arizona.”

Medmen Enterprises Inc (OTCMKTS:MMNFF), together with its subsidiaries, operates in the cannabis space in the United States.

MMNFF, more broadly, is a leading cannabis company in the U.S. with assets and operations across the country. Based in Los Angeles, MedMen brings expertise and capital to the cannabis industry and is one of the nation’s largest financial supporters of progressive marijuana laws.

The company cultivates, produces, possesses, uses, and distributes/retails cannabis in the recreational and medicinal cannabis marketplace. As of June 6, 2018, it owned and operated 18 licensed cannabis facilities under the MedMen brand name in California, Nevada, and New York.

The company frames itself as “the preeminent cannabis company in the United States” with multiple assets and operations in California, Nevada, New York, and Florida. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing, and retail, and is one of the most well-recognized cannabis brands in the world today.

Headquartered in Los Angeles, MedMen employs more than 800 workers across the United States. It was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to re-define our society’s relationship with cannabis. MedMen supports sensible, clear and just drug laws.

The Company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates.

The company is headquartered in Culver City, California. MedMen Enterprises Inc. is a subsidiary of The Medmen Of Nevada 2 Llc.

Moreover, the company operates as a cannabis company in the United States. The company cultivates, produces, possesses, uses, and distributes/retails cannabis in the recreational and medicinal cannabis marketplace. It owns and operates 19 licensed facilities in California, Florida, Nevada, and New York. The company is headquartered in Culver City, California.

 

Onward and Upward

As noted above, MMNFF just announced that it has signed a definitive agreement to acquire control of Kannaboost Technology Inc. and CSI Solutions LLC, collectively referred to as “Level Up,” in a cash and stock transaction valued at $33,000,000.

The stock is up on the news. Overall, shares of MMNFF have rallied about 20% over the past week. That sets up an interesting context for the action tomorrow. Shares of the stock have powered higher over the past month, rallying roughly 42% in that time on strong overall action.

“We have worked tremendously hard to build a company that puts the needs of patients in our local communities first,” said Michael Colburn, co-founder of Level Up. “This marks an exciting new chapter for our brands and for the medical marijuana patients who have supported us,” added Daryll DeSantis, Level Up co-founder.

Medmen Enterprises Inc (OTCMKTS:MMNFF) has about $12.2M in cash on the books against to a mountain of over $86M in total current liabilities. The company has been pulling in significant revenues, with over $7M in Q1 of this year, representing over 630% quarterly y/y growth on the top line.

Continue Reading

MARKETS

Medmen Enterprises Inc (OTCMKTS:MMNFF) Levels Up with New Acquisition

Published

on

Medmen Enterprises Inc (OTCMKTS:MMNFF) shares ripped on Thursday to break above the stock’s 50-day simple moving average. The move came apparently in response to the company’s announcement that it has signed a definitive agreement to acquire control of Kannaboost Technology Inc. and CSI Solutions LLC, collectively referred to as “Level Up,” in a cash and stock transaction valued at $33,000,000.

According to the release, “Level Up holds licenses for two vertically-integrated operations in Arizona, which include retail locations in Scottsdale and Tempe, as well as 25,000 square feet of cultivation and production capacity in Tempe and Phoenix. As part of the transaction, the Company will also receive a 40 percent stake in top-selling brand K.I.N.D. Concentrates, which is currently distributed in over 90 percent of the dispensaries in Arizona.”

Medmen Enterprises Inc (OTCMKTS:MMNFF), together with its subsidiaries, operates in the cannabis space in the United States.

MMNFF, more broadly, is a leading cannabis company in the U.S. with assets and operations across the country. Based in Los Angeles, MedMen brings expertise and capital to the cannabis industry and is one of the nation’s largest financial supporters of progressive marijuana laws.

The company cultivates, produces, possesses, uses, and distributes/retails cannabis in the recreational and medicinal cannabis marketplace. As of June 6, 2018, it owned and operated 18 licensed cannabis facilities under the MedMen brand name in California, Nevada, and New York.

The company frames itself as “the preeminent cannabis company in the United States” with multiple assets and operations in California, Nevada, New York, and Florida. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing, and retail, and is one of the most well-recognized cannabis brands in the world today.

Headquartered in Los Angeles, MedMen employs more than 800 workers across the United States. It was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to re-define our society’s relationship with cannabis. MedMen supports sensible, clear and just drug laws.

The Company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates.

The company is headquartered in Culver City, California. MedMen Enterprises Inc. is a subsidiary of The Medmen Of Nevada 2 Llc.

Moreover, the company operates as a cannabis company in the United States. The company cultivates, produces, possesses, uses, and distributes/retails cannabis in the recreational and medicinal cannabis marketplace. It owns and operates 19 licensed facilities in California, Florida, Nevada, and New York. The company is headquartered in Culver City, California.

 

A Boost

As we discussed earlier, MMNFF just announced that it has signed a definitive agreement to acquire control of Kannaboost Technology Inc. and CSI Solutions LLC, collectively referred to as “Level Up,” in a cash and stock transaction valued at $33,000,000.

“This acquisition strengthens our presence in one of the top cannabis markets in the U.S.,” said Adam Bierman, MedMen chief executive and co-founder. “We will continue to identify highly accretive transactions in core states and remain laser-focused on executing our retail playbook.”

MMNFF has responded well, rallying about 11% over the past five days, with this news clearly driving the action. Shares of the stock have powered higher over the past month, rallying roughly 34% in that time on strong overall action.

“We have worked tremendously hard to build a company that puts the needs of patients in our local communities first,” said Michael Colburn, co-founder of Level Up. “This marks an exciting new chapter for our brands and for the medical marijuana patients who have supported us,” added Daryll DeSantis, Level Up co-founder.

Medmen Enterprises Inc (OTCMKTS:MMNFF) had no reported sales in its last quarterly financial data. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($0 against $0, respectively).

Continue Reading
Advertisement

Trading Symbol

OTC: PLSI

The Next Big Global Cannabis Trade


FEATURED STORIES

Business20 hours ago

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Subsidiary’s Cannabis Product Performs Remarkably

Post Views: 173 OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is an industry leader in the development of cannabinoid-based therapies. Some of...

Business21 hours ago

Glance Technologies Inc (OTCMKTS:GLNNF) Communicates To Shareholder Through A Letter

Post Views: 67 Glance Technologies Inc (OTCMKTS:GLNNF) owns the dynamic mobile payment and loyalty technology platform known as Glance Pay®....

Business2 days ago

Green Organic Dutchman Holdings (OTCMKTS:TGODF) To Review Financing Alternatives For Construction Purposes

Post Views: 138 Green Organic Dutchman Holdings (OTCMKTS:TGODF) has, over the years, been focusing on the production of premium organic...

Business2 days ago

HEXO (OTCMKTS:HYYWF) Expects To Post Net Revenues Of $16.5 Million in Q4 2019 And $48.5 Million For FY 2019

Post Views: 133 HEXO (OTCMKTS:HYYWF) expects to post net revenues of up to $16.5 million in Q4 2019. The company...

Business5 days ago

LeafBuyer Technologies Inc. (OTCMKT:LBUY) Reports 59% YoY Growth In Revenue Following Optimization Of Its Platforms

Post Views: 218 LeafBuyer Technologies Inc. (OTCMKT:LBUY) has announced that its annual revenue for FY 2019 grew by 59%, reflecting...

Business5 days ago

High Tide Inc. (OTCMKTS:HITIF) Report Impressive Q3 Financial Results with Revenue Growing 281%

Post Views: 171 High Tide Inc. (OTCMKTS:HITIF) has announced an inspiring financial result for its third quarter of 2019. The...

Business6 days ago

Kalytera Therapeutics Inc (OTCMKTS:KALTF) Provides Details About Its Latest Notice Of Allowance

Post Views: 156 Kalytera Therapeutics Inc (OTCMKTS:KALTF) has today revealed details regarding the EU Patent Application Number 14791611.8. According to...

Business6 days ago

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Engages Cellular Biologist David A. Judd In An Interview

Post Views: 835 Pharmacyte Biotech Inc (OTCMKTS:PMCB) uses its live-cell encapsulation technology known as Cell-in-a-Box®  for the treatment of diabetes...

Business7 days ago

CV Sciences Inc (OTCMKTS:CVSI) enters a Distribution Agreement With Harris Teeter

Post Views: 150 CV Sciences Inc (OTCMKTS:CVSI) today announced its business collaboration with Harris Teeter. These two business giants target...

Business7 days ago

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Speaks Out On Its CAUMZ(TM) Kit

Post Views: 160 Tetra Bio Pharma Inc (OTCMKTS:TBPMF) is one of the leaders in the cannabinoid-based therapeutics sector. Some of...

Whats Hot

CULTIVATING

SHAREHOLDER VALUE

 

Trading Symbol

CSE: CHOO
OTCQB: CHOOF

Choom Holdings Inc. CSE: CHOO | OTCQB: CHOOF